Keep Moving Forward's Fundraising Page

Those who know me understand my endless goal of moving FORWARD. No matter what the goal, focus on what you want for an outcome, break the goal down into manageable steps, and keep inching FORWARD. Look at setbacks as mere "corrections" and try again. Keep moving FORWARD!

When I was diagnosed with Endometrial Stromal Sarcoma in 2018, this mindset was literally a lifesaver…then again in 2020…and again in 2021. Along with my team at Dana-Farber’s Sarcoma Center, a supportive family and the Grace of God, I have achieved an acceptable quality of life because of great discoveries. Without Dana-Farber’s research, expertise, and willingness to move FORWARD in discovering therapies to combat soft tissue sarcoma, I would not have been given a life renewed with more time to build precious memories with my family.

Please join me in helping the research team move FORWARD. Together we can help prolong more lives. One hundred percent of your contribution goes toward soft tissue sarcoma research. 

With love and gratitude,

 ~Mary Madore

“Dana-Farber and their Sarcoma Center are dedicated to the assessment, treatment and rehabilitation of soft tissue sarcoma diagnoses. Led by dedicated specialists in the pathologic and radiologic investigation of soft tissue sarcoma, the Sarcoma Center applies novel soft-tissue reconstructive techniques and provides access to promising cutting-edge therapies in the field. Unfortunately, the nature of a soft tissue sarcoma diagnosis often requires a combination of surgery, chemotherapy, and radiation therapy. As such, Dana-Farber deploys a team approach to treatment to manage these complicated cases.”

 “Soft tissue sarcoma is an uncommon cancer, defined as an ‘orphan’ disease, resulting in lower levels of support from government agencies, the primary funders of cancer research. Moreover, pharmaceutical companies are often reluctant to allocate time and resources toward developing new therapies for this disease given its rarity. Nevertheless, technological improvements and an increasing number of patient samples available for research have led to a growing molecular understanding of sarcoma at Dana-Farber as a complex set of distinct diseases, pointing to new targets for therapy. While formidable, we know these challenges are surmountable. Dana-Farber has the talent, resources, and determination to make a real impact against this difficult disease.”